Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q92765

UPID:
SFRP3_HUMAN

ALTERNATIVE NAMES:
Frezzled; Fritz; Frizzled-related protein 1; FrzB-1

ALTERNATIVE UPACC:
Q92765; O00181; Q99686

BACKGROUND:
The protein Secreted frizzled-related protein 3, with aliases such as Frezzled and Frizzled-related protein 1, is integral to the modulation of Wnt signaling pathways. It interacts with Wnts to regulate cell proliferation and differentiation, particularly in limb development and chondrocyte maturation. Its role as a Wnt8 signaling antagonist is essential for proper long bone formation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Osteoarthritis 1, characterized by joint cartilage degradation and bone remodeling, SFRP3 represents a promising target for therapeutic intervention. Understanding the role of SFRP3 could open doors to potential therapeutic strategies aimed at mitigating the debilitating effects of osteoarthritis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.